MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Lixte Biotechnology Holdings ROA Ratio 2011-2026 | LIXT
Annual ROA Ratio Lixte Biotechnology Holdings
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -118.07 | -113.51 | -132.1 | -62.44 | -91.33 | -49.19 | -132.19 | -492.54 | -476.96 | -512.92 | -245.51 | -118.17 | -480.92 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -49.19 | -512.92 | -232.76 |
Quarterly ROA Ratio Lixte Biotechnology Holdings
| 2025-Q3 | 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -217.99 | -219.44 | -115.5 | -134.96 | -130.72 | -104.94 | -126.62 | -128.83 | -94.2 | -81.18 | -100.74 | -98.63 | -103.29 | -65.38 | -96.01 | -107.09 | -90.29 | -45.1 | -85.48 | -95.23 | -110.94 | -79.28 | -103.12 | -86.58 | -72.29 | -41.15 | -74.95 | -84.91 | -97.75 | -100.57 | -249.83 | -365.3 | -471.95 | -373.43 | -503.82 | -484.94 | -440.61 | -374.31 | -467.28 | -429.86 | -483.6 | -402.66 | -458.76 | -421.88 | -350.51 | -368.56 | -572.74 | -720.83 | -858.92 | -612.55 | -1093.73 | -1370.73 | -1647.73 | -1443.55 | -481.18 | -481.18 | -481.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -41.15 | -1647.73 | -342.19 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-275.96 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
AIkido Pharma
AIKI
|
-31.2 | - | 1.93 % | $ 17.4 M | USA |
 |
Akouos
AKUS
|
-31.09 | - | 0.23 % | $ 488 M | USA |
 |
Akero Therapeutics
AKRO
|
-30.52 | - | - | $ 3.67 B | USA |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M |  China |
 |
Amarin Corporation plc
AMRN
|
-5.78 | $ 14.67 | -0.07 % | $ 6.09 B |  Irlanda |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
23.87 | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
-11.27 | - | -0.23 % | $ 916 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
-206.44 | - | 10.36 % | $ 9.8 M | USA |
 |
Aptinyx
APTX
|
-97.25 | - | -39.0 % | $ 4.57 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
-78.56 | - | -6.81 % | $ 3.04 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Avenue Therapeutics
ATXI
|
-437.72 | - | -52.27 % | $ 4.45 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-489.29 | - | - | $ 7.46 M |  Israel |
 |
Atreca
BCEL
|
-62.67 | - | -11.76 % | $ 5.79 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
bluebird bio
BLUE
|
-34.23 | - | - | $ 546 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Cabaletta Bio
CABA
|
-101.68 | $ 2.82 | 1.44 % | $ 283 M | USA |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-289.96 | - | -9.65 % | $ 45.9 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-28.19 | $ 1.29 | -3.01 % | $ 329 M | Britain |
 |
CEL-SCI Corporation
CVM
|
-102.18 | $ 3.47 | -1.7 % | $ 221 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Denali Therapeutics
DNLI
|
-30.77 | $ 19.74 | -12.17 % | $ 3.25 B | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
-94.17 | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
-30.95 | - | - | $ 3.74 B | USA |
 |
Enlivex Therapeutics Ltd.
ENLV
|
-54.23 | $ 1.09 | -9.17 % | $ 22.4 M | Israel |
 |
Enochian Biosciences
ENOB
|
-2162.69 | - | - | $ 40.5 M | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Equillium
EQ
|
-70.24 | $ 2.06 | - | $ 118 M | USA |
 |
Esperion Therapeutics
ESPR
|
-4.87 | $ 2.85 | 3.26 % | $ 592 M | USA |
 |
Eton Pharmaceuticals
ETON
|
-4.99 | $ 23.45 | -1.64 % | $ 631 M | USA |
 |
China SXT Pharmaceuticals
SXTC
|
-15.25 | $ 1.32 | -5.2 % | $ 1.88 M | China |
 |
Bellerophon Therapeutics
BLPH
|
-249.92 | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
-25.67 | $ 47.55 | 0.98 % | $ 4.28 B |  Schweiz |
 |
Arbutus Biopharma Corporation
ABUS
|
-35.41 | $ 4.45 | -1.77 % | $ 853 M | Canada |
 |
Allakos
ALLK
|
-76.23 | - | - | $ 28.6 M | USA |